No Data
No Data
Aligos Therapeutics Initiated With a Buy at Lucid Capital
Earnings Preview: ALGS to Report Financial Results Pre-market on May 06
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
Aligos Therapeutics Announces Eight Abstracts Accepted For Presentation At EASL Congress 2025 In Amsterdam , Netherlands
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $70
Express News | Aligos Therapeutics Inc Files for Offering of up to 6.2 Mln Common Shares by the Selling Securityholders - SEC Filing